Rakovina Therapeutics Inc., a biopharmaceutical company focused on AI-powered cancer therapies, will attend the 2025 BIO International Convention from June 16th to 19th in Boston. At the event, Rakovina will showcase its pipeline of novel DNA damage response inhibitors, including drug candidates discovered through its proprietary AI-driven platforms.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.